Clinical Report: Administration of [225Ac]Ac-PSMA-617 in mCRPC and Meningioma

Overview

This case study reports the administration of [225Ac]Ac-PSMA-617 in a 77-year-old male with metastatic castration-resistant prostate cancer and intracranial meningioma. The treatment resulted in a significant decrease in PSA levels and meningioma size, highlighting the potential of PSMA RLT in treating non-prostatic tumors.

Background

Prostate cancer is the most commonly diagnosed cancer among men globally, while meningioma is a prevalent primary brain tumor. The combination of these two conditions is rare, making effective treatment challenging. Prostate-specific membrane antigen radioligand therapy (PSMA RLT) represents a promising therapeutic approach due to PSMA expression in both tumor types.

Data Highlights

Key Findings

• The patient experienced a 99.8% decrease in PSA levels after treatment.
• Meningioma size decreased by 90.6% following four administrations of [225Ac]Ac-PSMA-617.
• High-grade xerostomia was noted as an unfavorable symptom post-treatment.
• Hematological parameters remained stable throughout the observation period.
• PSMA expression is prevalent in both prostate cancer and meningioma, supporting the use of PSMA RLT.

Clinical Implications

The findings suggest that [225Ac]Ac-PSMA-617 may be an effective treatment option for patients with both metastatic castration-resistant prostate cancer and meningioma. Clinicians should monitor for potential side effects, such as xerostomia, while considering this therapy.

Conclusion

This case report provides evidence for the efficacy of [225Ac]Ac-PSMA-617 in treating metastatic castration-resistant prostate cancer and meningioma, warranting further investigation into its broader application.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication | FDA
9. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis
10. Prostate-Specific Membrane Antigen Expression in Meningioma: A Promising Theranostic Target - PMC